no more compounding tirzepatide Compounded Compounded Tirzepatide

When only basal insulin is used for treatment, the original oral hypoglycemic drugs are maintained and insulin stimulants do not need to be stopped

The incidence of gastrointestinal adverse events was 72.5% with CagriSema versus 34.4% with placebo, predominantly transient and mild to moderate in severity

In contrast, the medication's blood pressure-lowering properties may provide improvement in cardiovascular risk factors for patients with type 2 diabetes, many of whom have concurrent hypertension as part of the metabolic syndrome

An early diagnosis and prompt treatment also reduce the risk of developing DKA with the diagnosis of type 1 diabetes